Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity

DexCom

GoodRx Holdings

Hims & Hers Health

23andMe

Oscar Health

Teladoc

Tempus AI Inc

Waystar Holding Corp

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

CarGurus

Globus Medical

Texas Roadhouse

Investors might be well served by expanding beyond the S&P 500.

Four hidden gems in the stock market from a five-star fund manager

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders

I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adjacent solutions.

Progyny: Rating Downgrade On Uncertain Growth Outlook

I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST).

Progyny, Inc. to Present at Jefferies London Healthcare Conference

Why Progyny Stock Crashed Today

Progyny, Inc. PGNY reported worse-than-expected third-quarter sales results and issued FY24 revenue guidance below estimates.

These Analysts Slash Their Forecasts On Progyny Following Q3 Results

Progyny, Inc (NASDAQ:PGNY ) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Allen Lutz - Bank of America Sarah James - Cantor Fitzgerald Michael Cherny - Leering Partners Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Stephanie Davis - Barclays Scott Schoenhaus - KeyBanc Richard Close - Canaccord Genuity David Larsen - BTIG Operator Good day, and welcome to the Progyny, Inc. Third Quarter Earnings Conference Call. At this time all participants have been placed on listen-only mode.

Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript

Progyny (PGNY) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.16 per share a year ago.

Progyny (PGNY) Tops Q3 Earnings Estimates

Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025

Progyny, Inc. Announces Third Quarter 2024 Results

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fertility benefits provider Progyny, Inc. (NASDAQ: PGNY) is under intense scrutiny following the unexpected announcement of a major client's departure.

Progyny (PGNY) Client Retention Narrative Under Examination - Hagens Berman

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024.

Progyny, Inc. Announces Details for Its Third Quarter 2024 Results Report

PGNY Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCICSO, CA / ACCESSWIRE / October 16, 2024 / Hagens Berman urges Progyny, Inc. (NASDAQ:PGNY) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys.

Progyny (PGNY) Crashes After Losing Significant Client - Hagens Berman

Progyny has had a rough start to the year, with the share price declining by double digits in response to both Q1'24 and Q2'24. In September, they filed an 8-K informing investors that they lost their largest client, accounting for 13% of revenue. Shares declined 30% as a result. This article reviews the year for PGNY so far, outlines why I am reluctant to pick up more shares at these depressed prices, and why the fertility space remains interesting.

Progyny: Poor Year Raises Concerns For Future (Downgrade)

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!

NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Progyny, Inc. (PGNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

PGNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Progyny, Inc. investment

NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Encourages Progyny, Inc. (PGNY) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

Progyny, Inc. (PGNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK CITY, NY / ACCESSWIRE / September 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PGNY.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Progyny, Inc. (PGNY) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.

News for Progyny Stock (PGNY)